Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

TTCR is also a predictor for PFS of the patients who were treated ARATA both whole cohort and post-docetaxel.

Keyphrases